Emerging therapies for respiratory diseases

Drug News and Perspectives

Volumn 20, Issue 9, 2007, Pages 593-600

  Lock, Ruth ^a,c   Collingwood, Steve ^a,c   Ratcliffe, Andrew ^b,c  

^a Novartis ^*  (United Kingdom)

^b UCB   (United Kingdom)

^c Society for Medicines Research (SMR) Committee

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; ACLIDINIUM BROMIDE; ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE PLUS FORMOTEROL; CZC 13788; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; INDACATEROL; IPRATROPIUM BROMIDE; MONTELUKAST; MUSCARINIC RECEPTOR BLOCKING AGENT; PROTEIN INHIBITOR; RSD 931; SALBUTAMOL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VRT 325; VX 770;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLITIS; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; NEBULIZER; PRURITUS; RESPIRATORY TRACT DISEASE;

ACETATES; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; BUDESONIDE; DRUG COMBINATIONS; DRUG THERAPY; ETHANOLAMINES; HUMANS; LEUKOTRIENE ANTAGONISTS; MOLECULAR STRUCTURE; QUINOLINES; RESPIRATORY TRACT DISEASES;

EID: 41649097754     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Barry, P.W. and O'Callaghan, C. The output of budesonide from nebulizers. J Allergy Clin Immunol 1998, 102(2): 321-2.
2. O'Callaghan, C., Lynch, J., Cant, M. and Robertson, C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax 1993, 48(6): 603-6.
3. Brown, R. and Schanker, L. Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos 1983, 11(4): 355-60.
4. Schanker, L., Mitchell, E. and Brown, R. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos 1985, 14(1): 79-88.
5. Patton, J., Fishburn, C. and Weers, J. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1(4): 338-44.
6. Tronde, A., Norden, B., Jeppsson, A.B. et al. Drug absorption from the isolated perfused rat lung: correlations with drug physicochemical properties and epithelial permeability. J Drug Target. 2003, 11(1): 61-74.
7. Disse, B., Speck, G.A., Rominger, K.L., Witek, T.J. and Hammer, R. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999, 64(6-7): 457-64.
8. Barnes, P. The pharmacological properties of tiotropium. Chest 2000, 117(2): 63S-6S.
9. Esmailpour, N., Högger, P., Rabe, K.F., Heitmann, U., Nakashima, M. and Rhdewald, P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10(7): 1496-9.
10. Thorsson, L., Edsbäcker, S., Källén, A. and Löfdahl, C.G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001, 52(5): 529-38.
11. Jendbro, M., Johansson, C.J., Strandberg, P., Falk-Nilsson, H. and Edsbäcker, S. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001, 29(5): 769-76.
12. Thurmond, R.L., Desai, P.J., Dunford, P.J. et al. A potent and selective histamine H4 receptor anatagonist with anti-inflammatory properties. J Pharmacol Exp Ther 2004, 309(1): 404-13.
13. Zhang, M., Venable, J.D. and Thurmond, R.L. The histamine H4 receptor in autoimmune disease. Expert Opin Investig Drugs 2006, 15(11): 1443-52.
14. Zhang, M., Thurmond, R.L. and Dunford, P.J. The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders. Pharmacol Ther 2007, 113(3): 594-606.
15. Cuenoud, B. and Fairhurst, R.A., inventors; Novartis AG and Novartis Pharma GmhH, applicants. Benzothiazole derivatives hav ing beta-2-adrenoreceptor agonist activity. Patent WO 2004016601. February 26, 2004.
16. Van Goor, F., Straley, K.S., Cao, D. et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006, 290(6): L1117-30.
17. Sorbera, L.A., Serradell, N. and Bolós, J. Fluticasone furoate. Drugs Fut 2007, 32(1): 12-16.
18. Barker, M., Clackers, M., Copley, R. et al. Dissociated nonsteroidal glucocorticoid receptor modulators; Discovery of the agonist trigger in a tetrahydronaphthalene-ben zoxazine series J Med Chem 2006, 49(14): 4216-31.
19. Clackers, M., Coe, D.M., Demaine, D.A. et al. Non-steroidal glucocorticoid agonists - The discovery of aryl pyrazoles as A-ring mimetics Bioorg Med Chem Lett 2007, 17(17): 4737-45.